دورية أكاديمية
أعرض في EDS

Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.

التفاصيل البيبلوغرافية
العنوان: Frequency of beryllium-specific, central memory CD4+ T cells in blood determines proliferative response.
المؤلفون: Fontenot AP; Division of Clinical Immunology, Department of Medicine, University of Colorado Health Sciences Center, Denver, Colorado, USA. andrew.fontenot@uchsc.edu, Palmer BE, Sullivan AK, Joslin FG, Wilson CC, Maier LA, Newman LS, Kotzin BL
المصدر: The Journal of clinical investigation [J Clin Invest] 2005 Oct; Vol. 115 (10), pp. 2886-93. Date of Electronic Publication: 2005 Sep 08.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
اللغة: English
بيانات الدورية: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0021-9738 (Print) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : Ann Arbor, MI : American Society for Clinical Investigation
Original Publication: New Haven [etc.] American Society for Clinical Investigation.
مواضيع طبية MeSH: Berylliosis/*immunology , Beryllium/*pharmacology , CD4-Positive T-Lymphocytes/*immunology , Immunologic Memory/*drug effects , Lymphocyte Activation/*drug effects , T-Lymphocyte Subsets/*immunology, Aged ; Berylliosis/blood ; Beryllium/immunology ; Cell Proliferation/drug effects ; Cells, Cultured ; Chronic Disease ; Female ; Humans ; Immunologic Memory/immunology ; Lung/immunology ; Lung/pathology ; Lymphocyte Activation/immunology ; Male ; Middle Aged
مستخلص: Beryllium exposure can lead to the development of beryllium-specific CD4+ T cells and chronic beryllium disease (CBD), which is characterized by the presence of lung granulomas and a CD4+ T cell alveolitis. Studies have documented the presence of proliferating and cytokine-secreting CD4+ T cells in blood of CBD patients after beryllium stimulation. However, some patients were noted to have cytokine-secreting CD4 T cells in blood in the absence of beryllium-induced proliferation, and overall, the correlation between the 2 types of responses was poor. We hypothesized that the relative proportion of memory T cell subsets determined antigen-specific proliferation. In most CBD patients, the majority of beryllium-specific CD4+ T cells in blood expressed an effector memory T cell maturation phenotype. However, the ability of blood cells to proliferate in the presence of beryllium strongly correlated with the fraction expressing a central memory T cell phenotype. In addition, we found a direct correlation between the percentage of beryllium-specific CD4+ T(EM) cells in blood and T cell lymphocytosis in the lung. Together, these findings indicate that the functional capability of antigen-specific CD4+ T cells is determined by the relative proportion of memory T cell subsets, which may reflect internal organ involvement.
References: Tissue Antigens. 2003 Dec;62(6):449-58. (PMID: 14617028)
J Clin Invest. 2003 Sep;112(5):776-84. (PMID: 12952926)
Blood. 2004 Feb 1;103(3):966-72. (PMID: 12958069)
Lancet. 2004 Feb 7;363(9407):415-6. (PMID: 14962519)
J Immunol. 2004 Mar 1;172(5):3337-47. (PMID: 14978142)
J Exp Med. 2004 Jul 19;200(2):255-60. (PMID: 15249595)
Am J Ind Med. 2004 Nov;46(5):453-62. (PMID: 15490468)
Ann Intern Med. 1988 May;108(5):687-93. (PMID: 3282464)
Am Rev Respir Dis. 1989 Jun;139(6):1479-86. (PMID: 2729754)
J Allergy Clin Immunol. 1991 Jul;88(1):54-60. (PMID: 2071785)
Environ Health Perspect. 1996 Oct;104 Suppl 5:937-43. (PMID: 8933038)
Environ Health Perspect. 1996 Oct;104 Suppl 5:953-6. (PMID: 8933041)
Am J Respir Cell Mol Biol. 1998 Apr;18(4):581-9. (PMID: 9533947)
J Immunol. 1999 Jul 15;163(2):1019-26. (PMID: 10395700)
Am J Respir Crit Care Med. 2005 Jan 1;171(1):54-60. (PMID: 15374840)
J Allergy Clin Immunol. 2005 May;115(5):1036-42. (PMID: 15867863)
Nature. 1999 Oct 14;401(6754):708-12. (PMID: 10537110)
Science. 2000 Oct 6;290(5489):92-7. (PMID: 11021806)
Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12717-22. (PMID: 11050177)
Fed Regist. 1999 Dec 8;64(235):68854-914. (PMID: 11010683)
J Immunol. 2001 Mar 1;166(5):3549-55. (PMID: 11207315)
Appl Occup Environ Hyg. 2001 May;16(5):514-20. (PMID: 11370931)
Clin Immunol. 2001 Jul;100(1):4-14. (PMID: 11414740)
J Clin Invest. 2001 Sep;108(6):805-6. (PMID: 11560949)
J Exp Med. 2001 Dec 17;194(12):1711-9. (PMID: 11748273)
J Virol. 2002 Jun;76(12):5925-36. (PMID: 12021325)
J Clin Invest. 2002 Nov;110(10):1473-82. (PMID: 12438445)
Toxicology. 2003 Feb 1;183(1-3):39-56. (PMID: 12504341)
Nat Immunol. 2003 Sep;4(9):835-42. (PMID: 12942084)
J Exp Med. 2003 Dec 15;198(12):1909-22. (PMID: 14676302)
معلومات مُعتمدة: P01 ES011810 United States ES NIEHS NIH HHS; ES06358 United States ES NIEHS NIH HHS; ES011810 United States ES NIEHS NIH HHS; HL62410 United States HL NHLBI NIH HHS; R01 HL062410 United States HL NHLBI NIH HHS; M01-RR-0051 United States RR NCRR NIH HHS; M01 RR000051 United States RR NCRR NIH HHS
المشرفين على المادة: OW5102UV6N (Beryllium)
تواريخ الأحداث: Date Created: 20050910 Date Completed: 20051212 Latest Revision: 20181113
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC1199530
DOI: 10.1172/JCI24908
PMID: 16151531
قاعدة البيانات: MEDLINE
الوصف
تدمد:0021-9738
DOI:10.1172/JCI24908